Novel Fusion Model Combines Hypoxia and Immune Signatures to Predict Survival in HCC Patients Undergoing TACE Therapy
A groundbreaking multicentre study published in Gut has developed an innovative multimodal prognostication model that combines hypoxia-related and immune phenotype-related signatures to accurately predict survival outcomes in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolisation (TACE). The clinical-radiologic model (CRM) demonstrated superior performance in stratifying patient risk compared to existing clinical models, potentially enabling more personalised treatment decision-making.
